Anteris Technologies Global Corp. (NASDAQ:AVR)
| Market Cap | 749.66M+78.9% |
| Revenue (ttm) | 2.24M-9.6% |
| Net Income | -103.57M-23.4% |
| EPS | -2.76+15.1% |
| Shares Out | 97.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,495,558 |
| Open | 7.97 |
| Previous Close | 7.61 |
| Day's Range | 7.66 - 7.99 |
| 52-Week Range | 3.30 - 11.06 |
| Beta | 0.73 |
| Analysts | Buy |
| Price Target | 18.00(+133.46%) |
| Earnings Date | Nov 11, 2026 |
Anteris Technologies Global Corp. has a live Insider Score.
Scored on 0 qualifying trades from 0 insiders in the last 90 days.
About AVR
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$AVR stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AVR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AVR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AVR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
AVR Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New AVR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AVR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AVR
| ETF | Est. Holding Size |
|---|---|
| IWMiShares Russell 2000 ETF | $15.50M |
| VXFVanguard Extended Market ETF | $7.66M |
| VTWOVanguard Russell 2000 ETF | $4.05M |
| SCHASchwab U.S. Small-Cap ETF | $3.28M |
| XHEState Street SPDR S&P Health Care Equipment ETF | $2.35M |
| IWCiShares Micro-Cap ETF | $1.89M |
Estimated from each fund’s disclosed top holdings × AUM
AVR Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AVR’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score